<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041573</url>
  </required_header>
  <id_info>
    <org_study_id>IC51-323</org_study_id>
    <nct_id>NCT01041573</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population</brief_title>
  <official_title>Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population. Open Label, Randomized, Active Controlled, Phase 3 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the systemic and local safety profile of purified
      inactivated Japanese Encephalitis Virus (JEV) vaccine IC51 administered in two doses in a 28
      days interval up to Month 7 after the first IC51 vaccination in a pediatric population from
      endemic regions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination</measure>
    <time_frame>until Day 56</time_frame>
    <description>Comparing study participants 1 year and above receiving IC51 0.25mL, IC51 0.5 mL and Havrix</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) for JEV Neutralizing Antibodies and SCR at Days 0, 56 and at Month 7</measure>
    <time_frame>Day 0, 56 and at Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With SAEs and Medically Attended AEs up to Month 7</measure>
    <time_frame>up to Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Solicited Local and Systemic AEs</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Unsolicited AEs up to Day 56 and up to Month 7</measure>
    <time_frame>Day 56 and up to Month 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Subjects With Abnormal Laboratory Parameters</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1869</enrollment>
  <condition>Encephalitis</condition>
  <arm_group>
    <arm_group_label>IC51 0.5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IC51 0.25 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix 720</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Havrix®720 0.5 ml im. at day 0 and month 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IC51 Japanese Encephalitis</intervention_name>
    <description>6 mcg or 3 mcg im. at day 0 and day 28</description>
    <arm_group_label>IC51 0.5 mL</arm_group_label>
    <arm_group_label>IC51 0.25 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix®720</intervention_name>
    <description>0.5 ml im. at day 0 and month 7</description>
    <arm_group_label>Havrix 720</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar</intervention_name>
    <description>0.5 ml im. at day 0 and day 56 and month 7</description>
    <arm_group_label>Prevnar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female healthy children and adolescents aged &gt; 2 months to &lt; 18 years at the
             time of first vaccination.

          -  Written informed consent by the subject's legal representative(s), according to local
             requirements, and written informed assent of the subject, if applicable.

          -  Female subjects: either no childbearing potential or negative pregnancy test, for
             females after menarche willingness to practice a reliable method of contraception.

        Exclusion Criteria:

          -  Clinical manifestation of Japanese Encephalitis

          -  History of Flavivirus vaccination (including any investigational vaccines)

          -  History of vaccination with HAVRIX®720 and/or Prevnar®

          -  History of immunodeficiency or immunosuppressive therapy

          -  Known HIV, HBV or HCV infection

          -  History of hypersensitivity reactions to other vaccines

          -  Acute febrile infection at each visit during which the subject receives a vaccination

          -  Active or passive immunization within 2 weeks prior to the first IC51 vaccination and
             up to the second IC51 vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Kadlecek</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Alabang Muninlupa City</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, UP-Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <removed_countries>
    <country>Malaysia</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2009</study_first_posted>
  <results_first_submitted>January 16, 2014</results_first_submitted>
  <results_first_submitted_qc>January 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2014</results_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Japanese Encephalitis Vaccine</keyword>
  <keyword>endemic countries</keyword>
  <keyword>to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IC51 0.5 mL</title>
          <description>Japanese Encephalitis Vaccine 6mcg i.m. at day 0 and day 28</description>
        </group>
        <group group_id="P2">
          <title>IC51 0.25 mL</title>
          <description>Japanese Encephalitis Vaccine 3mcg i.m. at day 0 and day 28</description>
        </group>
        <group group_id="P3">
          <title>Havrix 720</title>
          <description>Havrix®720 0.5 ml i.m. at day 0 and month 7</description>
        </group>
        <group group_id="P4">
          <title>Prevnar</title>
          <description>Prevnar 0.5 ml i.m. at day 0 and day 56 and month 7 or 0.5 ml i.m. at day 0, day 28 and day 56 and month 7-13</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="540"/>
                <participants group_id="P2" count="871"/>
                <participants group_id="P3" count="394"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="535"/>
                <participants group_id="P2" count="858"/>
                <participants group_id="P3" count="387"/>
                <participants group_id="P4" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>relocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>further blood extraction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>positive to anti-HCV</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IC51 0.5 mL</title>
          <description>Japanese Encephalitis Vaccine 6mcg i.m. at day 0 and day 28</description>
        </group>
        <group group_id="B2">
          <title>IC51 0.25 mL</title>
          <description>Japanese Encephalitis Vaccine 3mcg i.m. at day 0 and day 28</description>
        </group>
        <group group_id="B3">
          <title>Havrix 720</title>
          <description>Havrix®720 0.5 ml i.m. at day 0 and month 7</description>
        </group>
        <group group_id="B4">
          <title>Prevnar</title>
          <description>Prevnar 0.5 ml i.m. at day 0 and day 56 and month 7 or 0.5 ml i.m. at day 0, day 28 and day56 and month 7-13</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="540"/>
            <count group_id="B2" value="871"/>
            <count group_id="B3" value="394"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="1869"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2 months - &lt; 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year - &lt; 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="640"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 years - &lt; 12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 years - &lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="449"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="422"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="540"/>
                    <measurement group_id="B2" value="871"/>
                    <measurement group_id="B3" value="394"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="1869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination</title>
        <description>Comparing study participants 1 year and above receiving IC51 0.25mL, IC51 0.5 mL and Havrix</description>
        <time_frame>until Day 56</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IC51, Subjects Aged &gt;= 1 Year</title>
            <description>IC51 Japanese Encephalitis: 6 mcg or 3 mcg im. at day 0 and day 28</description>
          </group>
          <group group_id="O2">
            <title>IC51, Subjects Aged &gt;= 2 Months to &lt;1 Year</title>
            <description>Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28</description>
          </group>
          <group group_id="O3">
            <title>Havrix 720</title>
            <description>Havrix®720 0.5 ml im. at day 0 and month 7</description>
          </group>
          <group group_id="O4">
            <title>Prevnar</title>
            <description>Subjects aged ≥ 2 to &lt; 6 months: 4 intramuscular vaccinations, Days 0, 28, 56 and Month 7‐13 (subjects aged ≥ 2 to &lt; 6 months were to receive the fourth Prevnar® vaccination when 12‐15 months old, i.e., the vaccination was to be performed outside the study, depending on the subject´s age at day of first vaccination).
Subjects aged ≥ 6 months to &lt; 1 year: 3 intramuscular vaccinations, Days 0, 56 and Month 7.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination</title>
          <description>Comparing study participants 1 year and above receiving IC51 0.25mL, IC51 0.5 mL and Havrix</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="394"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="14.1" upper_limit="18.2"/>
                    <measurement group_id="O2" value="38.2" lower_limit="29.8" upper_limit="47.1"/>
                    <measurement group_id="O3" value="14.2" lower_limit="10.9" upper_limit="18.1"/>
                    <measurement group_id="O4" value="42.2" lower_limit="29.9" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.641</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) for JEV Neutralizing Antibodies and SCR at Days 0, 56 and at Month 7</title>
        <time_frame>Day 0, 56 and at Month 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With SAEs and Medically Attended AEs up to Month 7</title>
        <time_frame>up to Month 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Solicited Local and Systemic AEs</title>
        <time_frame>study duration</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Unsolicited AEs up to Day 56 and up to Month 7</title>
        <time_frame>Day 56 and up to Month 7</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Subjects With Abnormal Laboratory Parameters</title>
        <time_frame>study duration</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months after first vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IC51 0.5 mL</title>
          <description>Japanese Encephalitis Vaccine 6mcg i.m. at day 0 and day 28</description>
        </group>
        <group group_id="E2">
          <title>IC51 0.25 mL</title>
          <description>Japanese Encephalitis Vaccine 3mcg i.m. at day 0 and day 28</description>
        </group>
        <group group_id="E3">
          <title>Havrix 720</title>
          <description>Havrix®720 0.5 ml i.m. at day 0 and month 7</description>
        </group>
        <group group_id="E4">
          <title>Prevnar</title>
          <description>Prevnar 0.5 ml i.m. at day 0 and day 56 and month 7 or 0.5 ml i.m. at day 0, day 28 and day 56 and month 7-13</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="540"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="394"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Familial Periodic Paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="871"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Meningitis Bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Typhoid Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="871"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="394"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Kawasaki´s Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="394"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="300" subjects_at_risk="540"/>
                <counts group_id="E2" subjects_affected="691" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="252" subjects_at_risk="394"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="871"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="394"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="540"/>
                <counts group_id="E2" events="69" subjects_affected="58" subjects_at_risk="871"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E2" events="113" subjects_affected="94" subjects_at_risk="871"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="35" subjects_at_risk="540"/>
                <counts group_id="E2" events="127" subjects_affected="122" subjects_at_risk="871"/>
                <counts group_id="E3" events="40" subjects_affected="36" subjects_at_risk="394"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <description>pain without touching, solicited local</description>
                <counts group_id="E1" events="74" subjects_affected="65" subjects_at_risk="532"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="228"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <description>pain upon touching, solicited local</description>
                <counts group_id="E1" events="55" subjects_affected="48" subjects_at_risk="540"/>
                <counts group_id="E2" events="40" subjects_affected="38" subjects_at_risk="871"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="394"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hardening</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="540"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="871"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="394"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="540"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="871"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="394"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>solicited local</description>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="540"/>
                <counts group_id="E2" events="93" subjects_affected="81" subjects_at_risk="871"/>
                <counts group_id="E3" events="25" subjects_affected="25" subjects_at_risk="394"/>
                <counts group_id="E4" events="30" subjects_affected="23" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="532"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="268"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="235"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="76" subjects_affected="61" subjects_at_risk="540"/>
                <counts group_id="E2" events="316" subjects_affected="244" subjects_at_risk="871"/>
                <counts group_id="E3" events="53" subjects_affected="49" subjects_at_risk="394"/>
                <counts group_id="E4" events="31" subjects_affected="24" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>solicitec systemic</description>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="540"/>
                <counts group_id="E2" events="111" subjects_affected="87" subjects_at_risk="871"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="394"/>
                <counts group_id="E4" events="16" subjects_affected="9" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Excessive Fatigue</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="540"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="871"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="394"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="72" subjects_affected="67" subjects_at_risk="540"/>
                <counts group_id="E2" events="414" subjects_affected="326" subjects_at_risk="871"/>
                <counts group_id="E3" events="115" subjects_affected="97" subjects_at_risk="394"/>
                <counts group_id="E4" events="50" subjects_affected="33" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="540"/>
                <counts group_id="E2" events="61" subjects_affected="58" subjects_at_risk="871"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="394"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="540"/>
                <counts group_id="E2" events="89" subjects_affected="77" subjects_at_risk="871"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="394"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="540"/>
                <counts group_id="E2" events="48" subjects_affected="45" subjects_at_risk="871"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="394"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="540"/>
                <counts group_id="E2" events="78" subjects_affected="65" subjects_at_risk="871"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="394"/>
                <counts group_id="E4" events="12" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="531"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="233"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Heat Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="540"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="871"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="394"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>solicited systemic</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="540"/>
                <counts group_id="E2" events="57" subjects_affected="49" subjects_at_risk="871"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="394"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager Clinical Research</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>+43 1 206 20 ext 1175</phone>
      <email>katrin.dubischar-kastner@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

